Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 9/20 | 0.49 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | C1S | P09871 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11422303 | 0.88 | PRSS1 (0.60) | KMT2APRSS1SMPD1PLA2G4B | |
| SCHEMBL3243431 | 0.85 | KMT2A (0.69) | KMT2APRSS1PLA2G4B | |
| SCHEMBL27674694 | 0.85 | NR4A2 (0.46) | KMT2ASMPD1 | |
| SCHEMBL5202638 | 0.84 | KMT2A (0.62) | KMT2ASMPD1PLA2G4B | |
| SCHEMBL5499950 | 0.83 | KMT2A (0.53) | KMT2APRSS1SMPD1F2PLG | |
| SCHEMBL8465014 | 0.83 | SMPD1 (0.68) | KMT2APRSS1SMPD1PLA2G4B | |
| SCHEMBL3487082 | 0.83 | KMT2A (0.53) | KMT2APRSS1SMPD1F2PLG | |
| SCHEMBL5200730 | 0.82 | KMT2A (0.73) | KMT2ASMPD1PLA2G4B | |
| SCHEMBL7843724 | 0.82 | KMT2A (0.51) | KMT2APRSS1SMPD1F2PLG | |
| SCHEMBL28693694 | 0.82 | KMT2A (0.69) | KMT2APRSS1PLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125087-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| WO-2010056195-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
| US-20100125087-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| US-20100125087-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| WO-2010056195-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125087-A1 | NEW COMPOUNDS 575 | PSEN1, PSEN2, BACE1 | KMT2A 3888/4885PRSS1 385/4885SMPD1 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.